Member Info for sadoldgit

If there were tox issues they would not be going ahead with a capsule.

Spot on Zylo.

All very logical to me as to why Tim should pursue the capsule route. Tim and co in a better position to make these decisions. Just a very brief outine below.AbstractA majority of new active pharmaceutical ingredients in development exhibit low aqueous solubility and poor dissolution and, thus, poor oral bioavailability.A number of approaches have been used to improve aqueous solubility and bioavailability. These have included particle size reduction; creation of amorphous solid dispersions (ASDs); use of solubilization formulations; crystal modification; and chemical modification. Amorphous Spray Dried Dispersions (SDDs) are molecularly dispersed mixtures of amorphous drug, polymers, and optionally, other excipients and are commonly used to increase apparent solubility and dissolution rate, thereby affording superior bioperformance for poorly soluble drugs. Spray-drying is a mature, robust and scalable technology that has been successfully applied to a number of commercial products and a large number of compounds under clinical development.This chapter addresses the formulation, process development, scale-up, and drug product considerations for preparing spray dried dispersions (SDDs). From Sareum RNS the following'• Development of improved drug product underway for first clinical studies; decision made to develop potentially higher-value capsule formulations rather than orally dosed solutions or suspensions means this stage is expected to complete during H1 2022.'Now why would you go through at great effort and create the crystallisation of a compound then compromise in any way shape or form when capsule formulations are clearly advantageous over a tablet product? All things being equal, is it any wonder that competitors products have such a failure rate in clinical trials. Attention to detail. This does not just mean what a compound can do, but also and of the upmost importance is where it may fall down, and rectify these issues before clinical trials go ahead.Most Tyk 2 inhibitors inhibit IL-6. Why is ours better and currently indicative of being far more successful with regards to efficacy and safety profile? Regards

Change of spike protein. This will most likely make current vaccinations very ineffective.

https://www.msn.com/en-gb/news/newsbirmingham/covid-variant-worst-weve-seen-so-far-could-spark-new-travel-restrictions/ar-AAR8AVd?ocid=uxbndlbing

Severe strain of covid in south Africa. A variant of concern. Flights from 6 countries halted,
B11529 is new variant.

New variant just come on news. Variant of delta evading natural immunity and vaccinations. Will update when hear more.

I will second that PCS1954. I really do trust this will come good and benefit those that need it most.
Regards

Which is the first Tyk2 selective tyrosine kinase inhibitor?
POETYK PSO-1 is the first Phase 3 trial evaluating the efficacy and safety of deucravacitinib, the first and only novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor in clinical studies across multiple immune-mediated diseases.

Glass eye. looks good and does sweet FA.

Janus kinases work best in pairs. Tyk 2 however not compatible with JAK3. Very little point in Tyk 2 and Jak2.

An optimum amount of Jak1, with a precise formulation administered easily, very accurately via an orally available capsule to maximise efficacy.

Anybody know of company that could make such a thing.

regards

27% of 2 million dollars from memory.

Thanks citizen 79. i enjoy your posts. You can argue costs and market manipulation but in the end we rely on the science. It is to our benefit and the poor buggers that need new more effective forms of treatment.

Regards

I have a feeling that moves are in place to secure adequate funding by external investors or to be more precise the current Peel Hunt clientele will want to own a bigger share as possible. Peel Hunt IMHO are frantically trading in an effort to lower the VWAP on which many investors and institutions rely. We are not a client of Peel Hunt as such. Their aim is to provide the best possible rate for the big investor.
VWAP is the abbreviation for volume-weighted average price, which is a technical analysis tool that shows the ratio of an asset's price to its total trade volume. It provides traders and investors with a measure of the average price at which a stock is traded over a given period of time.

VWAP is commonly used as a benchmark by investors who want to be more passive in the market – usually pension funds and mutual funds – and traders who want to ascertain whether a stock was bought or sold at a good price.

To calculate VWAP, you use the following equation:
VWAP = ?(amount of asset bought x asset price)/total shares bought that day.

The standard VWAP is calculated using all of the orders of a given trading day, but it can also be used to look at multiple time frames.

Sareum will need to raise funds of that we know. But once raised removes any doubt of financial difficulty in progressing our compounds. We cannot rely on Sierra to line our pockets. Forward planning is in place to secure the future of our compounds.

Any pharma that we become involved with will want to know the confirmed end toxicology results and reassurance that Sareum is financially solvent.

Regards

Why use a tablet as an oral route when capsule formulation can be mere efficient? Time, effort and money has gone into producing a probable worlds best TYK2 Jak 1 compound. This can be further enhanced by the capsule form or oral uptake? Do not spoil the barrel for a halfpenny of tar springs to mind.

Regards

Abstract
A majority of new active pharmaceutical ingredients in development exhibit low aqueous solubility and poor dissolution and, thus, poor oral bioavailability.

A number of approaches have been used to improve aqueous solubility and bioavailability. These have included particle size reduction; creation of amorphous solid dispersions (ASDs); use of solubilization formulations; crystal modification; and chemical modification. Amorphous Spray Dried Dispersions (SDDs) are molecularly dispersed mixtures of amorphous drug, polymers, and optionally, other excipients and are commonly used to increase apparent solubility and dissolution rate, thereby affording superior bioperformance for poorly soluble drugs. Spray-drying is a mature, robust and scalable technology that has been successfully applied to a number of commercial products and a large number of compounds under clinical development.
This chapter addresses the formulation, process development, scale-up, and drug product considerations for preparing spray dried dispersions (SDDs).

Just a couple of posts to follow here with regards to formulation issues and advantages of capsule formulation. This method of oral administration is more precise as you will find out when read. I cannot access more info on this as need to register to purchase download, but what I do have points out the all important attention to detail that Sareum have adopted and continue to do so.

Abstract
The use of capsules goes back to the early days of pharmacy, and since these early days capsules have evolved significantly to meet the current needs of the patient and pharmaceutical industry.

Some of the early developments in capsule technology occurred as pharmacy evolved from dispensing compounded medication to the dispensing of manufactured products; during this change there were numerous advances in gelatin, capsule shell design and high speed manufacturing equipment.

Currently the pharmaceutical industry is undergoing a sea change as the blockbuster drugs become harder and harder to find, more of the value of a drug product comes from a dosage form with advanced delivery capabilities that can improve therapeutic outcomes. For example, capsule filling technologies have been developed for the manufacture of multiparticulate delivery systems, multiple dosage form systems such as a tablet in a capsule, combination products and delivery systems with multiphasic release rates.

In addition, capsules have always played an important role in the drug development process because hand filling or semiautomatic filling capsule formulations have minimal requirements and can be quickly developed. Given this context, the chapter will discuss the capsule dosage form in the drug development process starting with a discussion of gelatin, the different types of capsules shells, formulation and manufacturing. Also, we will discuss specialty capsules and capsule fills.'

Regards

A rather long read but indicates the differences between 3 different inhibitors.

https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-1964-1

Volume is 57 million which is around 12 million short of shown combined trades and sells.

Buyers market at the moment. At the same time funds will be required and as they say, no pain, no gain. These looking for 'other options to finance ' have their pro's and cons.

Toxicology results expected very soon. I would hazard a guess that news of funding would closely follow toxicology results.

Regards

Science has not changed at all. If the science is not right it will just not cut it in trials.

Be interested to know their intentions on fund raising. Sareum must have some idea. Whether 5 10 or 20 million. The clients of PH will want in with a market cap as low as possible
It gives them a greater percentage of shares and bigger take of any profits.

Good medium.term but not short term as being witnessed here.

As soon as money is raised which by my thinking will be fairly soon then the share price ought to jump back up.

Unfortunately we are not privy to what is going on in the background.

Regards all

Sareum would be well aware of the patent law.

As i see it they have hung on until patent notification of granting received in US of A. They can reopen up grant anytime up until next April.
They will not let something so valuable slip by. It will add worth to the TYk2 compounds without doubt. Added value in negotiations too!
Its all about playing the game and Sareum have their cards firmly to their chest.

Slight change of topic here.
Zylo I also have been keeping an eye on SO recently with an eye on their SP. Something big I feel coming their way soon whether Momoletonib or our Sar737 compound. Either is great news for Sareum.

Regards to all

I would hazard a guess that Sareum are maximising their patent life for thr crystallisation of a compound.

Terminated applications
Your application will be terminated if you do not submit the right documents, forms and payment when asked to.

You may be able to reopen your application if you apply within 12 months of termination.

You need to be able to show:

why you failed to meet the requirements
that the failure was not intentional
when you became able to meet the requirements
It costs £150 to apply - this is not refundable.

Reopen your application
Download the reinstatement request form.

Send the form, your fee and any supporting evidence to IPO.

If your request is granted, you must meet the requirements within 2 months.